Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518257 | 0.98 | DPP7 (0.50) | DPP7SLC6A3SIGMAR1ADORA2AADORA1 | |
| SCHEMBL8647480 | 0.96 | DPP7 (0.47) | DPP7SLC6A3SIGMAR1ADORA2AADORA1 | |
| SCHEMBL10726346 | 0.91 | IDO1 (0.46) | DPP7SIGMAR1IDO1KMT2ATHRB | |
| Trifluoroacetic Acid SCHEMBL8843994 | 0.83 | L3MBTL1 (0.49) | DPP7ADORA2AADORA1KMT2ATDP1 | |
| SCHEMBL7695234 | 0.82 | SIGMAR1 (0.53) | SLC6A3SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL112951 | 0.82 | HTT (0.51) | SIGMAR1ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL7375501 | 0.79 | SIGMAR1 (0.56) | DPP7SLC6A3SIGMAR1IDO1TDP1 | |
| SCHEMBL7327938 | 0.78 | SIGMAR1 (0.54) | DPP7SLC6A3SIGMAR1IDO1TDP1 | |
| SCHEMBL5269158 | 0.77 | KMT2A (0.57) | SIGMAR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4675392 | 0.77 | CHRNB2 (0.57) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| EP-4308125-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4308125-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197761-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-103140580-B | Aminotransferase, gene encoding the same, and method for using the same | KANEKA CORP. (JP) | 2016-06-01 | — | — | CN | disclosed |
| EP-2537845-B1 | 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2537845-A1 | 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists | Eli Lilly and Company (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2235007-B1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7994164-B2 | Mineralocorticoid receptor antagonists and methods of use | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2235007-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009085584-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | TEIJIN PHARMA LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1676837-A1 | PROCESS FOR PRODUCING AMINOPYRROLIDINE DERIVATIVE AND INTERMEDIATE COMPOUND | Teijin Pharma Limited (JP) | 2006-07-05 | — | — | EP | disclosed |
| US-6646093-B2 | Extruding auxiliary for cement materials, a mortar thickening agent, an underwater concrete thickening agent, a ceramics forming binder and a moisturizer for hair cosmetics; water and shape retention. | MITSUI CHEMICALS, INC. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20020045724-A1 | Water-souluble polyurthane having comb-shaped hydrophobic group and application thereof | MITSUI TAKEDA CHEMICALS, INC. (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6369077-B1 | OSTEOPOROSIS, PERIODONTITIS, AND ARTHRITIS | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | NR3C2, MC2R, REN | DPP7 1996/4885SLC6A3 412/4885SIGMAR1 483/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | DPP7 1456/4885SLC6A3 313/4885SIGMAR1 576/4885 |
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | DPP7 639/4885SLC6A3 4320/4885SIGMAR1 4827/4885 |
| US-20020045724-A1 | Water-souluble polyurthane having comb-shaped hydrophobic group and application thereof | BMI1, ASH2L, HAT1 | DPP7 4707/4885SLC6A3 3127/4885SIGMAR1 2186/4885 |
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | ACKR3, CCR2, CCR5 | DPP7 1507/4885SLC6A3 1815/4885SIGMAR1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.